MCA logo
MCA logo
MCA logo

PUBLIC PORTAL

MCA logo

MEDICALLY REVIEWED

Tepotinib (Tepmetko) for METex14-altered NSCLC

lung cancer tepotinib (tepmetko)
Tepotinib (Tepmetko) was recently approved for the use of Non-Small Cell Lung Cancer (NSCLC). Find out about the Phase II VISION trial here.

Log In or Register as a healthcare professional to read the full article.

Picture of Kaye

Kaye

Kaye obtained her Masters of Pharmacy degree from the University College London and has spent the better part of her career as a clinical pharmacist in a tertiary care hospital. Her professional interests are centred on HEOR and HTA work, in hopes of ultimately influencing cost-effective decisions for patient care.

Share via

Also worth reading

People also read:

Looking for health news and information? Stay updated with MCA’s health articles!

By clicking Submit, I agree to receive health newsletters and updates on upcoming health events from Medical Channel Asia and its partners.

About Us

Advertise

Contact Us

My Account

Privacy Policy

FOLLOW MCA

Facebook-f Tiktok Youtube Instagram Linkedin-in Telegram-plane

ACCREDITATIONS

Looking for health news and information? Stay updated with MCA’s health articles!

By clicking Submit, I agree to receive health newsletters and updates on upcoming health events from Medical Channel Asia and its partners.

About Us

Advertise

Contact Us

Privacy Policy

FOLLOW MCA

Facebook-f Tiktok Youtube Instagram Linkedin-in Telegram-plane

ACCREDITATIONS

Copyright © Medical Channel Asia 2022. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.